vaccine pexels

Moderna’s previously booming stock price took a major hit on Wednesday, falling more than 15 per cent after an analyst warned that the company’s valuation was “unrealistic”, and unjustifiably inflated due to hype around the company’s COVID vaccine.

It marks the continuation of a concerning week for investors in the stock, as the losses continued for the second day in a row.

The drop seems to have been precipitated by the harsh analysis of Bank of America’s Geoff Meacham, who on Monday called the company’s valuation “ridiculous”, and “unjustifiable”.

For the company to meet his price target, shares would need to slide more than 75 per cent against prices on Monday.

Shares in competing vaccine manufacturer, BioNTech, were also down this week, but seemingly due to an opposing reason, as a US study showed that its vaccine, developed in collaboration with Pfizer, might be less effective against battling the Delta variant of COVID.

Two new studies of over 50,000 patients in the Mayo Clinic Health System showed that Moderna’s vaccine might actually be more effective against the more transmissible variant of the virus.

It found that the effectiveness of the BioNTech’s vaccine in preventing infection with the variant was only 42 per cent in July, compared to 76 per cent for Moderna’s.

Related

Ryanair

Ryanair announces Winter 2023 schedule cuts caused by major Boeing delivery delays

September 28, 2023
by Anthea Cachia

The airline was set to receive 27 aircraft between September and December but will now only receive half

World’s most popular search engine, Google, turns 25

September 27, 2023
by Anthea Cachia

In one way or another, Google has become an influential factor in the operations of everyday life

That’s all folks! Netflix officially marks the end of its DVD-mailing era this week

September 26, 2023
by Anthea Cachia

The rental system was meant to last around four to five years, but instead it went on for 25 years